A new study has identified significant predictive factors for patients with peritoneal metastasis of gastric cancer (PMGC) who underwent aggressive treatment strategies. The study focused on patients who received a combination of cytoreductive surgery (C-CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after responding to induction chemotherapy.
Key findings include:
Patients with a Ki-67 index lower than 10 had significantly better recurrence-free and overall survival.
Limited lymph node involvement (LNI < 2) and smaller omental lesion size (< 0.5 cm) were associated with improved outcomes.
The study retrospectively examined 62 patients and found that those with these favorable parameters had a higher likelihood of long-term survival. Cox regression analysis further confirmed that decreased Ki-67 expression and minimal lymph node involvement were independent factors for better prognosis.
These results underscore the importance of thorough preoperative assessment to identify patients who are likely to benefit most from an aggressive multimodal treatment approach. This approach includes initial induction chemotherapy, followed by surgery and HIPEC, and aims to maximize survival outcomes.
For detailed insights, read the full study here.
Leave a Reply